Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538597 | 0.83 | IDO1 (0.63) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL3278241 | 0.81 | IDO1 (0.61) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL14647652 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL3278237 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL29616489 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL17864241 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL109671 | 0.79 | IDO1 (0.65) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL8417818 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL147650 | 0.79 | DAO (0.46) | IDO1SLC6A4 | |
| SCHEMBL488748 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| US-7858631-B2 | Substituted pyrido [2,3-d] pyrimidinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| EP-1551834-B1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-25 | — | — | EP | claimed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | claimed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | claimed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | claimed |
| JP-2007511612-A | — | — | 2007-05-10 | — | — | JP | claimed |
| JP-2007501861-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1551834-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | claimed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | claimed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040019049-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | claimed |
| WO-2003099818-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2003-12-04 | — | — | WO | claimed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | IDO1 740/4885SLC6A2 1389/4885SLC6A4 248/4885 |
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | IDO1 1285/4885SLC6A2 1477/4885SLC6A4 421/4885 |
| US-20040019049-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | IDO1 711/4885SLC6A2 1714/4885SLC6A4 291/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | IDO1 1340/4885SLC6A2 1097/4885SLC6A4 177/4885 |
| US-20050124652-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | IDO1 1285/4885SLC6A2 1477/4885SLC6A4 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.